共 15 条
[1]
Barbieri F.L., Ryan K.J., Danazol: endocrine pharmacology and therapeutic applications, Am. J. Obstet. Gynecol., 141, (1981)
[2]
Monroe S.E., Blumenfeld Z., Andreyko J.L., Schriock E., Henzl M.R., Jaffe K.B., Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin), J. Clin. Endocrinol. Metab., 63, (1986)
[3]
Maheux R., Guillotteau C., Lemay A., Bastide A., Fazekas A.T.A., Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study, Am. J. Obstet. Gynecol., 152, (1983)
[4]
Maheux K., Lemay A., Merat P., Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyoma, Fertil. Steril., 47, (1987)
[5]
Andreyko J.L., Marshall L.A., Dumesic D.A., Jaffe R.B., Therapeutic uses of- gonadotropin-releasing hormone analogs, Obstet. Gynecol. Sury., 42, (1987)
[6]
Steingold K.A., Cedars M., Lu J.K.H., Randle D., Judd H.L., Meldrum D.R., Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist, Obstet. Gynecol., 69, (1987)
[7]
Gudmusson J.A., Ljunghall S., Berquist C., Wide L., Nillus S.J., Increased bone turnover during gonadotropin releasing hormone superagonist-induced ovulation inhibition, J. Clin. Endocrinol. Metab., 65, (1987)
[8]
Tummon I.S., Ali A., Pepping M.E., Radwanska E., Binor Z., Dmowsky W.P., Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol, Fertil. Steril., 49, (1988)
[9]
Henzl M.R., Corson S.L., Moghissi K., Buttram V., Berqvist C., Jacobson J., Administration of nasal nafarelin as compared with oral danazol for endometriosis, N. Engl. J. Med., 318, (1988)
[10]
Comitee F., Jensen P., Lewis A., Hutchinson K., Polan M.L., DeCherney A., GnRH analog therapy in endometriosis: impact on bone mass, (1987)